Key result
Discharge NLR ≥3.5 linked to ~3.5-fold higher risk of adverse 3-month heart failure outcomes.
Why the study?
Patients hospitalized for AHF face a high risk of death and rehospitalization during the early postdischarge vulnerable phase. Because systemic inflammation plays a central role in heart failure pathophysiology, this study evaluated the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) at discharge.
Does the neutrophil-to-lymphocyte ratio at discharge predict 3-month heart failure-free survival in patients hospitalized for acute heart failure?
Cohort (n=486)
Yes
Does the neutrophil-to-lymphocyte ratio at discharge predict 3-month heart failure-free survival in patients hospitalized for acute heart failure?
Neutrophil-to-lymphocyte ratio at discharge (≥3.5) is an independent predictor of 3-month mortality and heart failure events after acute heart failure hospitalization, adding incremental prognostic value beyond the MAGGIC score.
Answers are grounded in this paper and cite their sources.
Discharge NLR ≥3.5 was associated with worse 3-month HF-free survival; leaves open incremental value beyond MAGGIC in prospective validation.
Aims Patients hospitalized for acute heart failure (AHF) face a high risk of death and rehospitalization, particularly during the early postdischarge ‘vulnerable phase’. As systemic inflammation plays a central role in heart failure pathophysiology, we evaluated the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) at discharge. Methods We analyzed consecutive patients hospitalized for AHF enrolled in the OPPORTUNITIES registry. The primary outcome was 3-month heart failure-free survival (composite of all-cause death, heart transplantation, heart failure hospitalization, or urgent heart failure visit). The optimal NLR cutoff was derived using the Youden index. Cox regression models assessed associations with outcomes, adjusting for the MAGGIC score. Findings were externally tested in an independent cohort from the Mayo Clinic (Rochester, USA). Results Four hundred and eighty-six AHF patients were included; median age 77 (67–83); 37.9% women. Median NLR was 2.47 (interquartile range 1.81–3.63), and a cutoff of 3.5 was identified. Patients with NLR at least 3.5 had worse clinical profiles and significantly lower 3-month heart failure-free survival (68.7 vs. 89.8%, log-rank P < 0.001), with a more than three-fold increase in event risk [hazard ratio 3.5, 95% confidence interval (CI) 2.2–5.4]. NLR was independently associated with both the composite outcome and overall survival after adjustment for MAGGIC score (hazard ratio 1.16, 95% CI 1.09–1.23; hazard ratio 1.20, 95% CI 1.11–1.31; P < 0.001, respectively), improving model fit (likelihood ratio test: P < 0.001). Integration of NLR with MAGGIC score enabled stepwise risk stratification. Consistent findings were observed in an independent external cohort, supporting the association between NLR and short-term overall survival. Conclusion NLR at discharge is a readily available biomarker that may provide incremental prognostic information beyond established risk scores and may contribute to risk stratification during the vulnerable phase after AHF hospitalization.
No takes yet. Share an insight, caveat, or question.
Sciatti et al. (2026) conducted a cohort in Acute heart failure (n=486). Neutrophil-to-lymphocyte ratio (NLR) at discharge ≥3.5 vs. Neutrophil-to-lymphocyte ratio (NLR) at discharge <3.5 was evaluated on 3-month heart failure-free survival (composite of all-cause death, heart transplantation, heart failure hospitalization, or urgent heart failure visit) (HR 3.5, 95% CI 2.2-5.4, p=<0.001). A discharge neutrophil-to-lymphocyte ratio ≥3.5 predicted worse 3-month heart failure-free survival in acute heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: